The estimated Net Worth of Donald J Kellerman is at least $616 Mille dollars as of 31 March 2022. Dr Kellerman owns over 4,006 units of Zosano Pharma Corp stock worth over $31,545 and over the last 10 years he sold ZSAN stock worth over $2,226. In addition, he makes $582,223 as VP of Clinical Devel. & Medical Affairs at Zosano Pharma Corp.
Dr has made over 3 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 4,006 units of ZSAN stock worth $841 on 31 March 2022.
The largest trade he's ever made was buying 15,920 units of Zosano Pharma Corp stock on 19 August 2016 worth over $21,014. On average, Dr trades about 1,664 units every 158 days since 2014. As of 31 March 2022 he still owns at least 56,331 units of Zosano Pharma Corp stock.
You can see the complete history of Dr Kellerman stock trades at the bottom of the page.
Dr. Donald J. Kellerman is the VP of Clinical Devel. & Medical Affairs at Zosano Pharma Corp.
As the VP of Clinical Devel. & Medical Affairs of Zosano Pharma Corp, the total compensation of Dr Kellerman at Zosano Pharma Corp is $582,223. There are 1 executives at Zosano Pharma Corp getting paid more, with Steven Lo having the highest compensation of $756,275.
Dr Kellerman is 66, he's been the VP of Clinical Devel. & Medical Affairs of Zosano Pharma Corp since . There are no older and 8 younger executives at Zosano Pharma Corp.
Donald's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... e Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: